Biomimetic profiling

Experimental and computational simulation of physiological and pathophysiological conditions aims to accurately predict drug behaviour in living systems. By integrating in vitro, and in silico models, this approach enables a deeper understanding of pharmacokinetics and pharmacodynamics, as well as the identification of potential therapeutic and adverse effects.

This strategy contributes to:

• more reliable prediction of the clinical and pharmaceutical potential of new molecules,

• optimization of therapeutic protocols,

• reduction of drug development time and costs,

• advancement of personalized medicine based on individual biological parameters of patients.

This concept lies in the implementation of artificial intelligence, experimental models and advanced bioinformatics platforms to simulate patient-specific responses to therapy prior to clinical administration. This opens the path toward more precise, safer, and more effective treatments while minimizing risks and adverse effects.